On CNBC’s “Halftime Report Final Trades,” Jim Lebenthal, partner and chief market strategist at Cerity Partners, picked Cleveland-Cliffs Inc. (NYSE:CLF).
Citigroup analyst Alexander Hacking, on Oct. 30, maintained Cleveland-Cliffs with a Neutral and raised the price target from $12 to $14.
Don’t forget to check out our premarket coverage here
Bryn Talkington, managing partner of Requisite Capital Management, picked Invesco S&P 500 Equal Weight ETF (NYSE:RSP), which continues to go higher.
Stephen Weiss, chief investment officer and managing partner of Short Hills Capital Partners, named UnitedHealth Group Incorporated (NYY UNH) as his final trade.
Supporting his view, Morgan Stanley analyst Erin Wright, on Oct. 27, maintained an Overweight rating on UnitedHealth and raised the price target from $529 to $531.
Joseph M. Terranova, senior managing director for Virtus Investment Partners, recommended Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN).
On the earnings front, Regeneron Pharmaceuticals reported better-than-expected third-quarter 2026 results on Friday. Regeneron reported adjusted earnings of $20.07 per share, up 70% year over year and above the analyst consensus estimate of $16.19. Revenue surged 36% to $5.116 billion, beating Wall Street’s estimate of $4.542 billion.
Price Action
- Cleveland-Cliffs shares gained 0.1% to close at $14.27 on Monday.
- UnitedHealth Group shares declined 1.6% to close at $400.44.
- Invesco S&P 500 Equal Weight ETF rose 0.8% on Monday.
- Regeneron Pharmaceuticals shares gained 3.6% to settle at $961.26 during the session.
See More:
Top Value Stocks
Photo via Shutterstock
Recent Comments